In a recent study, researchers at the University of Missouri are identifying new minimally invasive biomarkers to develop a blood test for early detection of non-small cell lung cancer (NSCLC), one of two main types of lung cancer.
Credit: CC0 Public Domain In a recent study, researchers at the University of Missouri are identifying new minimally invasive biomarkers to develop a blood
Researchers have discovered a cell-to-cell communication network that helps tumors regrow following treatment.
In the fight against cancers, activating mutations in the RAS family of genes stand in the way of finding viable treatment options. Now, researchers have discovered that one of these mutations oncogenic RAS or RASV12 is also responsible for the regrowth of cancer cells following genotoxic therapy treatment, or drugs that cause damage to a cancer cell’s DNA in order to eliminate it from the body.
“Most of our knowledge of how cells respond to DNA damage is mainly derived from studies looking at the single cell level,” says Yves Chabu, an assistant professor at the University of Missouri.
Oncogenic RAS mutations are responsible for regrowth of cancer cells following genotoxic therapies
In the fight against cancers, activating mutations in the RAS family of genes stand in the way of finding viable treatment options. Now, scientists at the University of Missouri and Yale University have discovered that one of these mutations oncogenic RAS or RASV12 is also responsible for the regrowth of cancer cells following genotoxic therapy treatment, or drugs that cause damage to a cancer cell s DNA in order to eliminate it from the body.
Most of our knowledge of how cells respond to DNA damage is mainly derived from studies looking at the single cell level. Therefore, we don t know much about how tumor cells respond to DNA damage in the broader context of the tissue level, and what possible implications these responses might have on a tumor s relapse following genotoxic therapies.
Credit: University of Missouri
In the fight against cancers, activating mutations in the RAS family of genes stand in the way of finding viable treatment options. Now, scientists at the University of Missouri and Yale University have discovered that one of these mutations oncogenic RAS or RASV12 is also responsible for the regrowth of cancer cells following genotoxic therapy treatment, or drugs that cause damage to a cancer cell s DNA in order to eliminate it from the body. Most of our knowledge of how cells respond to DNA damage is mainly derived from studies looking at the single cell level, said Yves Chabu, an assistant professor in the MU College of Arts and Science. Therefore, we don t know much about how tumor cells respond to DNA damage in the broader context of the tissue level, and what possible implications these responses might have on a tumor s relapse following genotoxic therapies. To address this, we looked at how tissues containing patches of cells carryin